WCCT adds smoking rooms at Phase I facility

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/6okean)
(Image: Getty/6okean)

Related tags: WCCT, phase I

WCCT adds fully compliant smoking rooms at its Phase I Clinical Unit for clinical trials testing aerosolized and inhaled products.

The new 850 square foot smoking rooms use a controlled air supply system with a 3500 CFM exhaust rate for static extraction of contaminated air, according to the contract research organization (CRO). The Cypress, CA-based facility also was designed to enable expansion in the future.

Talia Nikolao Hight, MBA, VP of commercial operations, WCCT, said the smoking rooms provide a safe, isolated environment in which to conduct research into the effect of smoking combustible cigarettes or “vaping.”

Compliant with the California Clean Air Act, California Labor Code 6404.5, and California AB 13, the air in each room can be recycled through in approximately 60 seconds, providing a contaminate-free and stable testing environment for a variety of aerosol products, according to the company.

Additionally, the smoking rooms’ walls are coated with a synthetic dual-membrane sealant for cleaning. Staff also are required to use gowns and gloves at all times.

Hight explained that the major challenge in carrying out research involving nicotine is its chemical nature. “Nicotine tends to cling or adhere to any surface that it comes in contact with and can, therefore, contaminate blood or urine specimens that are specifically being collected to measure nicotine concentration,”​ she said.

“Any smoker (either staff or study participant) may have nicotine on their fingers or clothing that can possibly find its way into blood or urine collection tubes or even syringes,”​ Hight added.

According to the Centers for Disease Control and Protection (CDC)​ more than 3.6m US middle and high school students in 2018 reported having used electronic cigarettes (e-cigarettes) in the past 30 days, including 4.9% of middle school students and 20.8% of high school students.

Related topics: Clinical Development, Phase I-II

Related news

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more